Please find enclosed herewith the re-appointment of Internal Auditor of the Company for the financial year 2026-2027
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma Ltd's Board meeting on May 12, 2026 approved the audited standalone and consolidated financial results for FY 2026 (year ended March 31, 2026). The statutory auditor issued an unmodified (clean) opinion on both sets of results. Key financials show consolidated revenue declined from ₹84,622 lakh to ₹80,973 lakh, but net profit grew significantly from ₹9,613 lakh to ₹13,242 lakh (38% growth). Standalone PAT grew from ₹6,867 lakh to ₹9,687 lakh (41% growth). The Board recommended a final dividend of ₹1 per share (100% payout). M/s. BDO India Services Private Limited was reappointed as Internal Auditor for FY 2026-27. An exceptional item of ₹215.55 lakh (standalone) was recognized for past service cost due to implementation of the New Labour Code. The 41st AGM is scheduled for July 15, 2026.
The company delivered strong profit growth despite revenue decline, indicating improved operational efficiency and margin expansion. The clean audit and dividend declaration are positive signals for shareholders. The stock is listed on BSE (Scrip Code: 506197) and NSE (Symbol: BLISSGVS).